GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Gilead Sciences (GILD) reported Q2 2026 non-GAAP loss per share of $6.75 and revenue of $7.8B, both above consensus. Management raised 2026 product sales guidance excluding Veklury to $29.8B-$30.1B and lifted HIV sales growth outlook to 9%-10%. CEO cited HIV and PrEP strength, Trodelvy growth, and ongoing anito-cel launch prep.
How this was made
The 30-second read
Why it matters
The key tradable update is management raising 2026 product sales ex-Veklury and lifting HIV growth expectations, alongside quantified HIV/PrEP performance (HIV +12%, PrEP quarterly >$1B, PrEP at ~$4B annual run rate). The call also flags offsetting weakness in cell therapy (-14%) and a reduced Veklury outlook.
Market read
Guidance raises and quantified HIV/PrEP strength are likely to drive estimate revisions and near-term sentiment, while cell-therapy decline and Veklury cut act as counterweights.
What to watch
Veklury expectations were cut to about $300M from about $600M, and the guidance range for total product sales is only modestly widened, so the net impact depends on how investors weigh Veklury softness versus HIV/PrEP upside.
Background
Gilead used its Q2 2026 earnings call to emphasize base-business growth led by HIV and PrEP, while updating full-year guidance and discussing a busy second-half launch calendar.
Ticker impact
Gilead raised 2026 base-product sales guidance to $29.8B-$30.1B and lifted HIV growth outlook to 9%-10% on stronger Biktarvy/PrEP momentum.
Likely positive bias for GILD shares as guidance and HIV/PrEP demand indicators improve, though oncology/cell-therapy softness may temper upside.
The article provides specific, management-quoted guidance changes (product sales ex-Veklury and HIV growth) plus quantified business momentum (PrEP quarterly >$1B, HIV sales +12%, Biktarvy +7%). These are direct inputs to near-term estimates and sentiment.
Market effects
Strength in HIV and PrEP demand may support sentiment across HIV-focused pharma and competitive positioning around oral and long-acting prevention regimens.
Limited direct regional spillover; primarily affects US large-cap pharma sentiment.
Global HIV/PrEP market read-through, but the article is company-specific guidance rather than a broad regulatory or pricing shift.
Counterpoint
Oncology and cell therapy remain pressured, with cell therapy sales down 14% and only launch preparation progress, which could offset HIV/PrEP strength in valuation.
Key entities
- companyGilead Sciences, Inc.
Raised 2026 base-product sales and HIV growth outlook; highlighted HIV/PrEP momentum and provided oncology/cell-therapy launch and pipeline updates.
- productTrodelvy
Reported sales rose 26% YoY, supported by breast cancer demand and new first-line metastatic triple-negative breast cancer approvals.
- product_candidateanito-cel
Management discussed launch preparations ahead of a Dec. 23 regulatory decision.
- product_candidateGS-8824
Highlighted ovarian cancer data (61% confirmed objective response rate, 11-month median PFS) with potential registrational development starting as early as 2027.
